DoD Prostate Cancer, Idea Development Award | HT942524PCRPIDA

Opportunity Information: Apply for HT942524PCRPIDA

The FY24 Department of Defense (DoD) Prostate Cancer Research Program (PCRP) Idea Development Award (Funding Opportunity Number HT942524PCRPIDA; CFDA 12.420) is a discretionary grant opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to fund bold, original prostate cancer research concepts that go beyond incremental next steps and instead introduce genuinely new ways of thinking or new methods that could meaningfully advance the PCRP mission. The program is open to unrestricted eligible applicants, supports science and technology research and development, and uses a grant instrument (31 USC 6304).

At the center of this award is a strong preference for innovation and creativity. Competitive applications are expected to challenge existing assumptions, propose new paradigms, or reframe persistent prostate cancer problems from a fresh angle. The opportunity explicitly signals that simply extending published work in a straightforward way will not be viewed as innovative. Multidisciplinary approaches are encouraged, and the program is particularly welcoming to projects that integrate data science, bioinformatics, mathematical modeling, and other cross-cutting methods, including work that leverages unusual or uniquely informative study populations.

The second major theme is impact. Applicants must clearly connect their project to one or more FY24 PCRP Overarching Challenges and explain, in concrete terms, how the work could address those challenges. Reviewers will be looking for both near-term and long-term value: near-term in terms of what the project might deliver during the award period (for example, a validated model, a robust dataset, a new diagnostic approach), and long-term in terms of how success would shift the field or improve patient care. The intent is to fund projects that, if they work, would noticeably move prostate cancer research or clinical practice forward rather than produce only modest gains.

Preliminary data are treated as optional. Because the mechanism is meant to encourage high-risk, high-reward ideas, the DoD notes that preliminary results are encouraged but not required. If applicants do include unpublished preliminary data, it is expected to come from the PI or members of the proposing team. Either way, the proposal must rest on a sound scientific rationale supported by logical reasoning and/or a careful reading of existing literature, so even more speculative ideas still need a credible foundation and a clear plan to test the concept.

A distinct New Investigator category is built into this mechanism to bring in investigators who are early in their independent careers. New Investigator applications are reviewed with different personnel criteria and must include at least one collaborator with demonstrated prostate cancer research experience, backed by a track record of funding and publications. The proposal must explain why the collaboration is likely to work, how the collaborator(s) will strengthen the team, and how the partnership fills gaps in the new PI's expertise. While not strictly framed as mandatory in all cases, the program strongly encourages letters of collaboration that spell out the collaborator's role and level of commitment, and New Investigator applicants must meet specific eligibility rules described in the full announcement.

The award also supports multidisciplinary and multi-institutional projects, but it places real emphasis on planning for teamwork and execution. Applications that span multiple organizations must include a clear interaction plan describing how communication will happen, how research progress will be coordinated, how results will be shared, and how data will be transferred. Multi-institutional proposals must also address intellectual property considerations with an IP plan intended to avoid institutional barriers that could slow collaboration or threaten successful completion of the project.

On the research quality side, the program pushes applicants to adopt rigorous and reproducible study practices. Where relevant, investigators are encouraged to authenticate cell lines, ensure statistical rigor in animal and preclinical studies, and include experiments that speak to clinical relevance and translational potential. The announcement highlights standards aligned with transparent reporting and good experimental design principles described by Landis et al. (Nature, 2012), including randomization, blinding, sample size estimation, and clear data handling practices. The overall message is that even highly innovative projects need to be designed so their findings are credible, reproducible, and useful for eventual translation.

The funding opportunity encourages projects that capitalize on large existing patient datasets and resources, especially those that combine long-term health records, biorepositories, and pre-existing studies with modern genomics/proteomics and advanced analytics. It also encourages applicants to document access to essential resources; when a project depends on specialized datasets, repositories, or other unique infrastructure, the application should show that access exists at submission and include a plan for maintaining that access throughout the work. Letters of support demonstrating availability of key resources are strongly encouraged, particularly when access could be a limiting factor.

Programmatically, the announcement points to several areas of special interest. Applicants are encouraged to consider recommendations from the congressionally mandated Metastatic Cancer Task Force and propose ideas that align with those recommendations, as long as the work still fits within PCRP priorities and the boundaries of this funding mechanism. The DoD also explicitly welcomes innovative prostate cancer research involving nuclear medicine and related techniques, especially work that could enable earlier diagnosis, more effective treatment, and improved outcomes for active-duty Service Members and their families, including noninvasive precision imaging and targeted therapy approaches. More broadly, the program encourages collaboration among academia, industry, military services, the Department of Veterans Affairs, and other federal agencies, emphasizing that these partnerships can bring unique infrastructure and access to distinct clinical populations that can accelerate progress for Service Members, Veterans, and their families.

Clinical trials are not allowed under this award. The announcement uses the federal definition (45 CFR 46.102), meaning studies where human subjects are prospectively assigned to an intervention to evaluate effects on health-related outcomes are considered clinical trials and are prohibited. However, the award does allow certain types of clinical research that are observational or otherwise do not evaluate an intervention's safety or efficacy. Examples listed include studies of disease mechanisms in humans, diagnostic or detection studies such as biomarkers or imaging, health disparity research, technology development, epidemiology and behavioral studies that do not test an intervention, and outcomes or health services research that does not meet the clinical trial definition. The announcement also clarifies that some in vitro studies using human data/specimens may fall outside the definition of clinical research if they cannot be linked to living individuals and meet specific Common Rule exemption conditions.

Financially, applicants should plan for total direct costs across the full performance period of no more than $1.2 million. The DoD expects to allocate about $53.76 million total to support roughly 28 awards, though actual funding depends on federal funds availability, application volume, and results of peer and programmatic review. The original application closing date listed is July 19, 2024. Awards using FY24 funds are expected to be made no later than September 30, 2025, and those FY24 funds are anticipated to remain available for use until September 30, 2030, which matters for the government obligation window even though project timelines are governed by the individual award terms.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-05-01.
• Applicants must submit their applications by 2024-07-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 28 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524PCRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: